Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 500 of 1048 entries
View as:

Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT05406466 Org: User:
Start: 07/15/22 End: 08/16/24 Due: 08/16/25

clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06392217 Org: User:
Start: 03/12/24 End: 04/01/26 Due: 04/01/27

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Phase: N/A Priority: Normal
NCT ID: NCT04031703 Org: User:
Start: 01/01/11 End: 04/20/16 Due: 04/20/17

Effects of One-handed and Two-handed Mask Ventilation Techniques on Global and Regional Lung Ventilation

Phase: N/A Priority: Normal
NCT ID: NCT04617665 Org: User:
Start: 11/30/20 End: 12/31/20 Due: 12/31/21

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Phase: N/A Priority: Normal
NCT ID: NCT05223582 Org: User:
Start: 05/01/21 End: 12/31/23 Due: 12/31/24

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05675462 Org: User:
Start: 03/01/23 End: 12/30/25 Due: 12/30/26

Value of ctDNA in the Treatment of Multiple Primary Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05164510 Org: User:
Start: 12/31/21 End: 09/30/23 Due: 09/30/24

Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PET

Phase: N/A Priority: Normal
NCT ID: NCT05914402 Org: User:
Start: 06/18/23 End: 12/01/25 Due: 12/01/26

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Phase: N/A Priority: Normal
NCT ID: NCT04537286 Org: User:
Start: 08/25/20 End: 10/15/24 Due: 10/15/25

Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT04582968 Org: User:
Start: 01/02/20 End: 08/12/23 Due: 08/12/24

Novel Therapy Target in Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05577689 Org: User:
Start: 08/01/23 End: 12/01/28 Due: 12/01/29

Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07005557 Org: User:
Start: 06/15/25 End: 05/15/35 Due: 05/15/36

RGL-305+ Lymphoma + Exploratory Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT07006012 Org: User:
Start: 04/21/25 End: 12/31/31 Due: 12/31/32

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT05819060 Org: User:
Start: 04/30/23 End: 03/30/25 Due: 03/30/26

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02687490 Org: User:
Start: 02/24/17 End: 12/15/20 Due: 12/15/21

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Phase: N/A Priority: Normal
NCT ID: NCT02665702 Org: User:
Start: 01/31/16 End: 09/30/19 Due: 09/30/20

A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT06553781 Org: User:
Start: 09/01/24 End: 09/01/27 Due: 09/01/28

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Phase: N/A Priority: Normal
NCT ID: NCT05138159 Org: User:
Start: 12/01/21 End: 07/30/23 Due: 07/30/24

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05483543 Org: User:
Start: 06/20/22 End: 12/31/24 Due: 12/31/25

Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05643417 Org: User:
Start: 12/31/22 End: 10/31/24 Due: 10/31/25

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05634590 Org: User:
Start: 12/31/22 End: 12/31/25 Due: 12/31/26

Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02723526 Org: User:
Start: 03/31/16 End: 03/31/19 Due: 03/31/20

Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03532711 Org: User:
Start: 01/01/12 End: 12/31/16 Due: 12/31/17

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06973421 Org: User:
Start: 07/01/25 End: 06/30/28 Due: 06/30/29

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04535024 Org: User:
Start: 03/04/21 End: 12/31/22 Due: 12/31/23